⌘K
t
On 30 January 2025, Graham Paterson, Senior Independent Non-Executive Director of Diaceutics PLC, purchased 11,643 ordinary shares at 137.5 pence per share. Following this transaction, Paterson holds 85,141 Ordinary Shares, representing approximately 0.10% of Diaceutics PLC's issued share capital.
| Date | 31 Jan 2025 |
| Time | 09:13:08 |
| Category | Director/PDMR dealings |
| ID | 4627V |
Diaceutics PLC
Purchase of Shares and PDMR Shareholding
New York, Belfast and London, 31 January 2025 - Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to the pharma and biotech industry, announces that on 30 January 2025, Graham Paterson, the Senior Independent Non-Executive Director of Diaceutics PLC, purchased 11,643 ordinary shares of £0.002 in the capital of the Company ("Ordinary Shares") at a price of 137.5 pence per Ordinary Share. As a result of the purchase, Graham's shareholding is 85,141 Ordinary Shares, representing approximately 0.10% of the Company's issued share capital.
Enquiries:
|
Diaceutics PLC |
|
|
Ryan Keeling, Chief Executive Officer |
Tel: +44 (0)28 9040 6500 |
|
Nick Roberts, Chief Financial Officer |
investorrelations@diaceutics.com |
|
|
|
|
Canaccord Genuity Limited (Nomad & Broker) |
Tel: +44 (0)20 7253 8000 |
|
Simon Bridges, Andrew Potts, Harry Rees |
|
|
|
|
About Diaceutics
At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network ®.
|
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 |
|||||||
|
1 |
Details of the person discharging managerial responsibilities/person closely associated |
||||||
|
a. |
Name |
Graham Paterson |
|||||
|
2 |
Reason for notification |
|
|||||
|
a. |
Position/Status |
Non-Executive Director |
|||||
|
b. |
Initial notification/ Amendment |
Initial |
|||||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||||
|
a. |
Name |
Diaceutics PLC |
|||||
|
b. |
LEI |
213800VEWQBB39ZB8J81 |
|||||
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||||||
|
a. |
Description of the financial instrument, type of instrument |
Ordinary shares of £0.002 each
ISIN: GB00BJQTGV64 |
|||||
|
b. |
Nature of the transaction |
Purchase |
|||||
|
c. |
Price(s) and volume(s) |
|
Share purchase: |
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
||||
|
137.5 p |
11,643 |
|
|||||
|
|
|||||||
|
e. |
Date of the transaction |
30 January 2025 |
|||||
|
f. |
Place of the transaction |
AIM Market of the London Stock Exchange |
|||||